Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-label Study

Time frame: Baseline to Week 52 of the open-label study

Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-label Study

Time frame: Baseline to Week 52 of the open-label study

Mean Percent Change in Direct Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-label Study

Time frame: Baseline to Week 52 of the open-label study

Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-label Study

Time frame: Baseline to Week 52 in this open-label study

Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-label Study

Time frame: Baseline to Week 52 of the open-label study

Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-label Study

Time frame: Baseline to Week 52 of the open-label study

Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-label Study

Time frame: Baseline to Week 52 of the open-label study